We committed to developing a vaccine and treatments for COVID-19 as soon as it was known as a pandemic. Successfully fighting it requires global partnerships among countries, companies, and more. That’s why we’re working with Ridgeback Bio, to research a possible, new treatment for viral infections called, molnupiravir.
Here at Merck, we are also developing other COVID-19 vaccines and treatments. We are optimistic our industry’s efforts will create new vaccines and treatments at a faster rate to fight this pandemic.
The rise of the COVID-19 pandemic has highlighted how much communities of color can be overly impacted by global health issues. We must learn how safe and effective (how well they work) our treatments are for all people around the world.
We’ve taken steps to close diversity gaps in our clinical trials, including to:
Diversity is important to us. That’s why, at Merck, we’ll continue to foster discussion, create awareness, and empower research sites to recruit patients based on the impact of diseases in groups that might otherwise be under-represented in our research.